Showing 71-80 of 10619 results for "".
DermwireTV Extra: More than Skin Deep
https://practicaldermatology.com/videos/dermwire-tv/more-than-skin-deep/20153/Julie Block, President & CEO at the National Eczema Association, discusses the toll that a child's eczema can take on the whole family. Visit understandad.com to learn more and to access the new Blue’s Clues & You! Storybook.Scientifically Speaking: The Expanded Role for Microneedling
https://practicaldermatology.com/videos/scientifically-speaking/the-expanded-role-for-microneedling/20011/What's the role for microneedling in today's practice? What are the best strategies to optimize outcomes? In this edition of Scientifically Speaking, host Joel L. Cohen, MD gathers expert insights from Anna Guanche, MD; Mara Weinstein Velez, MD; and Doris Day, MD.DermWireTV: Pfizer, AbbVie JAKs for AD; Spray-on-Skin; Lubriderm Scholarships
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-pfizer-abbvie-jaks-for-ad-spray-on-skin-lubriderm-scholarships/20043/For the treatment of refractory moderate-to-severe atopic dermatitis, FDA has approved Pfizer’s Cibinqo (abrocitinib) for adults and AbbVie’s Rinvoq (upadacitinib) for patients 12 and older. Researchers at the Houston Methodist Research Institute have paired their patented RNA technologiIntergenerational Dermatology: Two Generations of Dermatologists Reflect on the Field
https://practicaldermatology.com/topics/general-topics/intergenerational-dermatology-two-generations-of-dermatologists-reflect-on-the-field-2/23937/With Heidi A. Waldorf, MD, and Donald S. Waldorf, MDDermWireTV: Pulse's CellFX, Soliton's RAP Technology, Belotero Balance (+), Restylane Defyne, Eczema Costs
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-pulses-cellfx-solitons-rap-technology-belotero-balance-restylane-defyne-eczema-costs/19899/The FDA has cleared Pulse Biosciences’ CellFX system, and a commercial rollout will begin soon. There’s another new option for treatment for legs with FDA clearance of Soliton’s Rapid Acoustic Pulse technology for cellulite. For eight percent of Americans with atopic dermatitis, anDermWireTV: Practices Reopen; Prescriber's Choice Expands; Sun Takes on Acne
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-practices-reopen-prescribers-choice-expands-sun-takes-on-acne/19810/Dermatology practices across the US are re-opening and professional associations are offering guidance, as states reduce restrictions. From Prescriber's Choice comes PC Direct for in-office use and PC Delivers for remote prescribing. Sun Dermatology’s Take on Acne advertising camScientifically Speaking: The Truth About Skincare
https://practicaldermatology.com/videos/scientifically-speaking/scientifically-speaking-the-truth-about-skincare/19876/From workhorse ingredients like antioxidants and retinol to newer molecules that address pigmentation and aging, there is a lot of noise in the skincare marketplace. And that's without talking about "natural" formulations. Joel L. Cohen, MD gets to the heart of the science, in a converCoding and Reimbursement Tips for 2022
https://practicaldermatology.com/topics/practice-management/coding-and-reimbursement-tips-for-2022/20045/After mitigating a proposed 10 percent cut in Medicare payments to a two percent cut, Mark Kaufmann, MD stresses the importance of dermatologists advocating for raising reimbursement rates. He also discusses best practices for billing and coding.Keeping Tech in Check
https://practicaldermatology.com/topics/practice-management/keeping-tech-in-check/18427/Dermatologist and their patients can benefit from advances in technology, but the key is that new tools and data are used properly. Neal Bhatia, MD asks Mark Kaufmann, MD how dermatologists can advocate for their specialty and what initiatives are underway.TOGETHER-PsO: Dual Therapy for Psoriasis and Obesity
https://practicaldermatology.com/videos/skin-minute/together-pso-dual-therapy-for-psoriasis-and-obesity/57262/Mark G. Lebwohl, MD, provides key takeaways and commentary on the results of the TOGETHER-PsO study, which looked at a combination therapy of ixekizumab (Taltz) and tirzepatide (Zepbound) in patients with both psoriasis and obesity.